Compare WMK & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WMK | MLTX |
|---|---|---|
| Founded | 1912 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 1994 | 2020 |
| Metric | WMK | MLTX |
|---|---|---|
| Price | $72.39 | $12.11 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $27.50 |
| AVG Volume (30 Days) | 123.4K | ★ 1.2M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.96% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.05 | N/A |
| Revenue | ★ $4,714,573,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $35.15 | ★ N/A |
| Revenue Growth | ★ 0.01 | N/A |
| 52 Week Low | $59.99 | $5.95 |
| 52 Week High | $83.74 | $62.75 |
| Indicator | WMK | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.08 | 21.38 |
| Support Level | $67.85 | $11.06 |
| Resistance Level | $72.51 | $19.24 |
| Average True Range (ATR) | 1.57 | 0.66 |
| MACD | 0.40 | -0.21 |
| Stochastic Oscillator | 66.58 | 4.79 |
Weis Markets Inc is a U.S.-based company that is principally engaged in retailing food products in Pennsylvania and surrounding states. The company's products mainly belong to the following categories: center-store goods, fresh goods, pharmacy services, fuel, and others. The center-store goods include groceries, dairy products, frozen foods, alcoholic beverages, and general merchandise items. The fresh goods include meats, seafood, floral, prepared foods, and bakery products. The center-store goods and fresh goods jointly account for the majority of the company's total revenue.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.